Advances in understanding and treating ADHD

BMC Medicine

Volumn 9, Issue , 2011, Pages

  Antshel, Kevin M ^a   Hargrave, Teresa M ^a   Simonescu, Mihai ^a   Kaul, Prashant ^a   Hendricks, Kaitlin ^a   Faraone, Stephen V ^a  

^a State University of New York Upstate Medical University: College of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 2 ADRENERGIC RECEPTOR; AMFEBUTAMONE; AMPHETAMINE; ATOMOXETINE; CLONIDINE; DEXAMPHETAMINE; DEXMETHYLPHENIDATE; GUANFACINE; IMIPRAMINE; INTUNIV; KAPVAY; LISDEXAMFETAMINE; METHAMPHETAMINE; METHYLPHENIDATE; MODAFINIL; REBOXETINE; UNCLASSIFIED DRUG; ADRENERGIC RECEPTOR AFFECTING AGENT; CENTRAL STIMULANT AGENT;

ABDOMINAL PAIN; ADRENERGIC TRANSMISSION; ANXIETY DISORDER; APPETITE DISORDER; ATTENTION DEFICIT DISORDER; BEDTIME DOSAGE; BEHAVIOR MODIFICATION; BLURRED VISION; CARDIOVASCULAR DISEASE; COGNITIVE THERAPY; COMORBIDITY; DECREASED APPETITE; DISABILITY; DISRUPTIVE BEHAVIOR; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG INDUCED HEADACHE; GASTROINTESTINAL IRRITATION; HEART ARRHYTHMIA; HEART PALPITATION; HEART RATE; HUMAN; HYPERTENSION; HYPOTENSION; INSOMNIA; IRRITABILITY; MOOD DISORDER; NERVOUSNESS; PATIENT COMPLIANCE; POPULATION; QUALITY OF LIFE; SEDATION; SEIZURE THRESHOLD; SHORT SURVEY; SIDE EFFECT; SLEEP DISORDER; SUICIDAL IDEATION; SWEATING; TIC; XEROSTOMIA; MEDICAL RESEARCH; METHODOLOGY; PATHOPHYSIOLOGY; REVIEW;

ADRENERGIC UPTAKE INHIBITORS; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; BIOMEDICAL RESEARCH; CENTRAL NERVOUS SYSTEM STIMULANTS; COGNITIVE THERAPY; HUMANS;

EID: 79958170868     PISSN: None     EISSN: 17417015     Source Type: Journal    
DOI: 10.1186/1741-7015-9-72     Document Type: Short Survey

References (134)

1. APA DSM-IV-TR. 2000, Washington, DC: American Psychiatric Association, APA.
2. Barbaresi WJ, Katusic SK, Colligan RC, Pankratz VS, Weaver AL, Weber KJ, Mrazek DA, Jacobsen SJ. How common is attention-deficit/hyperactivity disorder? Incidence in a population-based birth cohort in Rochester, Minn. Arch Pediatr Adolesc Med 2002, 156(3):217-224.
3. Kessler RC, Adler L, Barkley R, Biederman J, Conners CK, Demler O, Faraone SV, Greenhill LL, Howes MJ, Secnik K, et al. The prevalence and correlates of adult ADHD in the United States: results from the National Comorbidity Survey Replication. American Journal of Psychiatry 2006, 163(4):716-723. 10.1176/appi.ajp.163.4.716, 2859678, 16585449.
4. Lavigne JV, Gibbons RD, Christoffel KK, Arend R, Rosenbaum D, Binns H, Dawson N, Sobel H, Isaacs C. Prevalence rates and correlates of psychiatric disorders among preschool children. J Am Acad Child Adolesc Psychiatry 1996, 35(2):204-214. 10.1097/00004583-199602000-00014, 8720630.
5. Faraone SV, Sergeant J, Gillberg C, Biederman J. The worldwide prevalence of ADHD: is it an American condition?. World Psychiatry 2003, 2(2):104-113. 1525078, 16946912.
6. Polanczyk G, de Lima MS, Horta BL, Biederman J, Rohde LA. The worldwide prevalence of ADHD: a systematic review and metaregression analysis. Am J Psychiatry 2007, 164(6):942-948. 10.1176/appi.ajp.164.6.942, 17541055.
7. Bloom B, Cohen RA. Summary health statistics for U.S. children: National Health Interview Survey, 2006. 2007, 234:1-79. Statistics VH.
8. Levy F, Hay DA, McStephen M, Wood C, Waldman I. Attention-deficit hyperactivity disorder: a category or a continuum? Genetic analysis of a large-scale twin study. J Am Acad Child Adolesc Psychiatry 1997, 36(6):737-744. 10.1097/00004583-199706000-00009, 9183127.
9. Angold A, Costello EJ, Erkanli A. Comorbidity. J Child Psychol Psychiatry 1999, 40(1):57-87. 10.1111/1469-7610.00424, 10102726.
10. Biederman J, Newcorn J, Sprich S. Comorbidity of attention deficit hyperactivity disorder with conduct, depressive, anxiety, and other disorders. American Journal of Psychiatry 1991, 148(5):564-577.
11. Borland BL, Heckman HK. Hyperactive boys and their brothers: A 25-year follow-up study. Archives of General Psychiatry 1976, 33:669-675.
12. Morrison JR. Adult psychiatric disorders in parents of hyperactive children. American Journal of Psychiatry 1980, 137:825-827.
13. Biederman J, Faraone SV, Spencer T, Wilens T, Norman D, Lapey KA, Mick E, Lehman BK, Doyle A. Patterns of psychiatric comorbidity, cognition, and psychosocial functioning in adults with attention deficit hyperactivity disorder. Am J Psychiatry 1993, 150(12):1792-1798.
14. Heiligenstein E, Conyers LM, Berns AR, Miller MA. Preliminary normative data on DSM-IV attention deficit hyperactivity disorder in college students. J Am Coll Health 1998, 46(4):185-188. 10.1080/07448489809595609, 9519582.
15. Murphy K, Barkley RA. Attention deficit hyperactivity disorder adults: comorbidities and adaptive impairments. Compr Psychiatry 1996, 37(6):393-401. 10.1016/S0010-440X(96)90022-X, 8932963.
16. Shekim WO, Asarnow RF, Hess E, Zaucha K, Wheeler N. A clinical and demographic profile of a sample of adults with attention deficit hyperactivity disorder, residual state. Compr Psychiatry 1990, 31(5):416-425. 10.1016/0010-440X(90)90026-O, 2225800.
17. Barkley R, Murphy K, Fischer M. ADHD in adults: what the science says. 2007, New York: Guilford Press.
18. Lahey BB, Applegate B, McBurnett K, Biederman J, Greenhill L, Hynd GW, Barkley RA, Newcorn J, Jensen P, Richters J, et al. DSM-IV field trials for attention deficit hyperactivity disorder in children and adolescents. Am J Psychiatry 1994, 151(11):1673-1685.
19. Lopez-Munoz F, Alamo C, Quintero-Gutierrez FJ, Garcia-Garcia P. A bibliometric study of international scientific productivity in attention-deficit hyperactivity disorder covering the period 1980-2005. Eur Child Adolesc Psychiatry 2008, 17(6):381-391. 10.1007/s00787-008-0680-1, 18431538.
20. Levy F. Dopamine vs noradrenaline: inverted-U effects and ADHD theories. Aust N Z J Psychiatry 2009, 43(2):101-108. 10.1080/00048670802607238, 19153917.
21. Stahl SM. Mechanism of action of stimulants in attention-deficit/hyperactivity disorder. J Clin Psychiatry 2010, 71(1):12-13. 10.4088/JCP.09bs05890pur, 20129003.
22. Swanson JM, Volkow ND. Psychopharmacology: concepts and opinions about the use of stimulant medications. J Child Psychol Psychiatry 2009, 50(1-2):180-193. 10.1111/j.1469-7610.2008.02062.x, 2681087, 19220601.
23. Stahl SM. Mechanism of action of alpha 2A-adrenergic agonists in attention-deficit/hyperactivity disorder with or without oppositional symptoms. J Clin Psychiatry 2010, 71(3):223-224. 10.4088/JCP.09bs05899pur, 20331927.
24. Daughton JM, Kratochvil CJ. Review of ADHD pharmacotherapies: advantages, disadvantages, and clinical pearls. J Am Acad Child Adolesc Psychiatry 2009, 48(3):240-248. 10.1097/CHI.0b013e318197748f, 19242289.
25. May DE, Kratochvil CJ. Attention-deficit hyperactivity disorder: recent advances in paediatric pharmacotherapy. Drugs 2010, 70(1):15-40. 10.2165/11530540-000000000-00000, 20977288.
26. Chen CY, Gerhard T, Winterstein AG. Determinants of initial pharmacological treatment for youths with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol 2009, 19(2):187-195. 10.1089/cap.2008.096, 19364296.
27. Olfson M, Marcus S, Wan G. Stimulant dosing for children with ADHD: a medical claims analysis. J Am Acad Child Adolesc Psychiatry 2009, 48(1):51-59. 10.1097/CHI.0b013e31818b1c8f, 19218896.
28. Fulton BD, Scheffler RM, Hinshaw SP, Levine P, Stone S, Brown TT, Modrek S. National variation of ADHD diagnostic prevalence and medication use: health care providers and education policies. Psychiatr Serv 2009, 60(8):1075-1083. 10.1176/appi.ps.60.8.1075, 19648195.
29. Janknegt R, Faber A, Rodrigues Pereira R, Kalverdijk LJ. InforMatrix for attention deficit hyperactivity disorder. Expert Opin Pharmacother 2009, 10(5):755-772. 10.1517/14656560902765769, 19351226.
30. Harpur RA, Thompson M, Daley D, Abikoff H, Sonuga-Barke EJ. The attention-deficit/hyperactivity disorder medication-related attitudes of patients and their parents. J Child Adolesc Psychopharmacol 2008, 18(5):461-473. 10.1089/cap.2008.023, 18928411.
31. Berger I, Dor T, Nevo Y, Goldzweig G. Attitudes toward attention-deficit hyperactivity disorder (ADHD) treatment: parents' and children's perspectives. J Child Neurol 2008, 23(9):1036-1042. 10.1177/0883073808317726, 18487521.
32. Pappadopulos E, Jensen PS, Chait AR, Arnold LE, Swanson JM, Greenhill LL, Hechtman L, Chuang S, Wells KC, Pelham W, et al. Medication adherence in the MTA: saliva methylphenidate samples versus parent report and mediating effect of concomitant behavioral treatment. J Am Acad Child Adolesc Psychiatry 2009, 48(5):501-510. 10.1097/CHI.0b013e31819c23ed, 19307987.
33. Rabbani A, Alexander GC. Impact of family structure on stimulant use among children with attention-deficit/hyperactivity disorder. Health Serv Res 2009, 44(6):2060-2078. 10.1111/j.1475-6773.2009.01019.x, 19732168.
34. Brinkman WB, Sherman SN, Zmitrovich AR, Visscher MO, Crosby LE, Phelan KJ, Donovan EF. Parental angst making and revisiting decisions about treatment of attention-deficit/hyperactivity disorder. Pediatrics 2009, 124(2):580-589. 10.1542/peds.2008-2569, 19651580.
35. Thorell LB, Dahlstrom K. Children's self-reports on perceived effects on taking stimulant medication for ADHD. J Atten Disord 2009, 12(5):460-468. 10.1177/1087054708320430, 18685139.
36. McCarthy S, Asherson P, Coghill D, Hollis C, Murray M, Potts L, Sayal K, de Soysa R, Taylor E, Williams T, et al. Attention-deficit hyperactivity disorder: treatment discontinuation in adolescents and young adults. Br J Psychiatry 2009, 194(3):273-277. 10.1192/bjp.bp.107.045245, 19252159.
37. Faraone SV, Biederman J, Spencer TJ, Aleardi M. Comparing the efficacy of medications for ADHD using meta-analysis. MedGenMed 2006, 8(4):4.. 1868385, 17415287.
38. Chavez B, Sopko MA, Ehret MJ, Paulino RE, Goldberg KR, Angstadt K, Bogart GT. An update on central nervous system stimulant formulations in children and adolescents with attention-deficit/hyperactivity disorder. Ann Pharmacother 2009, 43(6):1084-1095. 10.1345/aph.1L523, 19470858.
39. Kim Y, Shin MS, Kim JW, Yoo HJ, Cho SC, Kim BN. Neurocognitive effects of switching from methylphenidate-IR to OROS-methylphenidate in children with ADHD. Hum Psychopharmacol 2009, 24(2):95-102. 10.1002/hup.1010, 19226534.
40. Chou WJ, Chou MC, Tzang RF, Hsu YC, Gau SS, Chen SJ, Wu YY, Huang YF, Liang HY, Cheng H. Better efficacy for the osmotic release oral system methylphenidate among poor adherents to immediate-release methylphenidate in the three ADHD subtypes. Psychiatry Clin Neurosci 2009, 63(2):167-175. 10.1111/j.1440-1819.2009.01937.x, 19335386.
41. Abikoff H, Nissley-Tsiopinis J, Gallagher R, Zambenedetti M, Seyffert M, Boorady R, McCarthy J. Effects of MPH-OROS on the organizational, time management, and planning behaviors of children with ADHD. J Am Acad Child Adolesc Psychiatry 2009, 48(2):166-175. 10.1097/CHI.0b013e3181930626, 19127171.
42. Childress AC, Spencer T, Lopez F, Gerstner O, Thulasiraman A, Muniz R, Post A. Efficacy and safety of dexmethylphenidate extended-release capsules administered once daily to children with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol 2009, 19(4):351-361. 10.1089/cap.2009.0007, 19702487.
43. Moen MD, Keam SJ. Dexmethylphenidate extended release: a review of its use in the treatment of attention-deficit hyperactivity disorder. CNS Drugs 2009, 23(12):1057-1083. 10.2165/11201140-000000000-00000, 19958043.
44. Faraone SV, Glatt SJ, Bukstein OG, Lopez FA, Arnold LE, Findling RL. Effects of once-daily oral and transdermal methylphenidate on sleep behavior of children with ADHD. J Atten Disord 2009, 12(4):308-315.
45. Wilens TE, Hammerness P, Martelon M, Brodziak K, Utzinger L, Wong P. A controlled trial of the methylphenidate transdermal system on before-school functioning in children with attention-deficit/hyperactivity disorder. J Clin Psychiatry 71(5):548-556.
46. Manos M, Frazier TW, Landgraf JM, Weiss M, Hodgkins P. HRQL and medication satisfaction in children with ADHD treated with the methylphenidate transdermal system. Curr Med Res Opin 2009, 25(12):3001-3010. 10.1185/03007990903388797, 19849639.
47. Gonzalez MA, Campbell D, Rubin J. Effects of application to two different skin sites on the pharmacokinetics of transdermal methylphenidate in pediatric patients with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol 2009, 19(3):227-232. 10.1089/cap.2008.0081, 19519257.
48. Garcia SP, Guimaraes J, Zampieri JF, Martinez AL, Polanczyk G, Rohde LA. Response to methylphenidate in children and adolescents with ADHD: does comorbid anxiety disorders matters?. J Neural Transm 2009, 116(5):631-636. 10.1007/s00702-009-0211-3, 19370390.
49. Biederman J, Monuteaux MC, Spencer T, Wilens TE, Faraone SV. Do stimulants protect against psychiatric disorders in youth with ADHD? A 10-year follow-up study. Pediatrics 2009, 124(1):71-78. 10.1542/peds.2008-3347, 2954591, 19564285.
50. Wilens TE, Adamson J, Monuteaux MC, Faraone SV, Schillinger M, Westerberg D, Biederman J. Effect of prior stimulant treatment for attention-deficit/hyperactivity disorder on subsequent risk for cigarette smoking and alcohol and drug use disorders in adolescents. Arch Pediatr Adolesc Med 2008, 162(10):916-921. 10.1001/archpedi.162.10.916, 2760975, 18838643.
51. Bloch MH, Panza KE, Landeros-Weisenberger A, Leckman JF. Meta-analysis: treatment of attention-deficit/hyperactivity disorder in children with comorbid tic disorders. J Am Acad Child Adolesc Psychiatry 2009, 48(9):884-893. 10.1097/CHI.0b013e3181b26e9f, 19625978.
52. Gadow KD, Nolan EE, Sverd J, Sprafkin J, Schneider J. Methylphenidate in children with oppositional defiant disorder and both comorbid chronic multiple tic disorder and ADHD. J Child Neurol 2008, 23(9):981-990. 10.1177/0883073808315412, 18474932.
53. Sonuga-Barke EJ, Coghill D, Wigal T, DeBacker M, Swanson J. Adverse reactions to methylphenidate treatment for attention-deficit/hyperactivity disorder: structure and associations with clinical characteristics and symptom control. J Child Adolesc Psychopharmacol 2009, 19(6):683-690. 10.1089/cap.2009.0024, 20035586.
54. Yu ZJ, Parker-Kotler C, Tran K, Weller RA, Weller EB. Peripheral vasculopathy associated with psychostimulant treatment in children with attention-deficit/hyperactivity disorder. Curr Psychiatry Rep 2010, 12(2):111-115. 10.1007/s11920-010-0093-y, 20425295.
55. Hammerness P, Wilens T, Mick E, Spencer T, Doyle R, McCreary M, Becker J, Biederman J. Cardiovascular effects of longer-term, high-dose OROS methylphenidate in adolescents with attention deficit hyperactivity disorder. J Pediatr 2009, 155(1):84-89, 89 e81. 10.1016/j.jpeds.2009.02.008, 19394037.
56. Mahon AD, Stephens BR, Cole AS. Exercise responses in boys with attention deficit/hyperactivity disorder: effects of stimulant medication. J Atten Disord 2008, 12(2):170-176.
57. Winterstein AG, Gerhard T, Shuster J, Saidi A. Cardiac safety of methylphenidate versus amphetamine salts in the treatment of ADHD. Pediatrics 2009, 124(1):e75-80. 10.1542/peds.2008-3138, 19564272.
58. Warren AE, Hamilton RM, Belanger SA, Gray C, Gow RM, Sanatani S, Cote JM, Lougheed J, LeBlanc J, Martin S, et al. Cardiac risk assessment before the use of stimulant medications in children and youth: A joint position statement by the Canadian Paediatric Society, the Canadian Cardiovascular Society, and the Canadian Academy of Child and Adolescent Psychiatry. Can J Cardiol 2009, 25(11):625-630. 10.1016/S0828-282X(09)70157-6, 2776560, 19898693.
59. Banaschewski T. Joint position of the Guideline Group of the European Network for Hyperkintetic Disorders (EUNETHYDIS) and the German Central ADHD Network for ECG Recording on methylphenidate prescriptions. Z Kinder Jugendpsychiatr Psychother 2008, 36(6):437-439.
60. Ponsa I, Ramos-Quiroga JA, Ribases M, Bosch R, Bielsa A, Ordeig MT, Morell M, Miro R, de Cid R, Estivill X, et al. Absence of cytogenetic effects in children and adults with attention-deficit/hyperactivity disorder treated with methylphenidate. Mutat Res 2009, 666(1-2):44-49.
61. Walitza S, Kampf K, Artamonov N, Romanos M, Gnana Oli R, Wirth S, Warnke A, Gerlach M, Stopper H. No elevated genomic damage in children and adolescents with attention deficit/hyperactivity disorder after methylphenidate therapy. Toxicol Lett 2009, 184(1):38-43. 10.1016/j.toxlet.2008.10.011, 19015014.
62. Faraone SV, Biederman J, Morley CP, Spencer TJ. Effect of stimulants on height and weight: a review of the literature. J Am Acad Child Adolesc Psychiatry 2008, 47(9):994-1009.
63. Graham J, Banaschewski T, Buitelaar J, Coghill D, Danckaerts M, Dittmann RW, Dopfner M, Hamilton R, Hollis C, Holtmann M, et al. European guidelines on managing adverse effects of medication for ADHD. Eur Child Adolesc Psychiatry 2011, 20(1):17-37. 10.1007/s00787-010-0140-6, 3012210, 21042924.
64. Setlik J, Bond GR, Ho M. Adolescent prescription ADHD medication abuse is rising along with prescriptions for these medications. Pediatrics 2009, 124(3):875-880. 10.1542/peds.2008-0931, 19706567.
65. Rabiner DL, Anastopoulos AD, Costello EJ, Hoyle RH, McCabe SE, Swartzwelder HS. The misuse and diversion of prescribed ADHD medications by college students. J Atten Disord 2009, 13(2):144-153. 10.1177/1087054708320414, 19448150.
66. Faraone SV, Wilens TE. Effect of stimulant medications for attention-deficit/hyperactivity disorder on later substance use and the potential for stimulant misuse, abuse, and diversion. J Clin Psychiatry 2007, 68(Suppl 11):15-22.
67. Kollins SH. ADHD, substance use disorders, and psychostimulant treatment: current literature and treatment guidelines. J Atten Disord 2008, 12(2):115-125.
68. Najib J. The efficacy and safety profile of lisdexamfetamine dimesylate, a prodrug of d-amphetamine, for the treatment of attention-deficit/hyperactivity disorder in children and adults. Clin Ther 2009, 31(1):142-176. 10.1016/j.clinthera.2009.01.015, 19243715.
69. Antonucci D, Kunins C, Manos M, Lopez FA, Kerney DL. Assessing effects of treatment with lisdexamfetamine dimesylate for pediatric ADHD using a parental survey. CNS Spectr 2010, 15(4):248-256.
70. Findling RL, Ginsberg LD, Jain R, Gao J. Effectiveness, safety, and tolerability of lisdexamfetamine dimesylate in children with attention-deficit/hyperactivity disorder: an open-label, dose-optimization study. J Child Adolesc Psychopharmacol 2009, 19(6):649-662. 10.1089/cap.2008.0165, 20035583.
71. Faraone SV, Spencer TJ, Kollins SH, Glatt SJ. Effects of lisdexamfetamine dimesylate treatment for ADHD on growth. J Am Acad Child Adolesc Psychiatry 49(1):24-32.
72. Boellner SW, Stark JG, Krishnan S, Zhang Y. Pharmacokinetics of lisdexamfetamine dimesylate and its active metabolite, d-amphetamine, with increasing oral doses of lisdexamfetamine dimesylate in children with attention-deficit/hyperactivity disorder: a single-dose, randomized, open-label, crossover study. Clin Ther 32(2):252-264.
73. Kahbazi M, Ghoreishi A, Rahiminejad F, Mohammadi MR, Kamalipour A, Akhondzadeh S. A randomized, double-blind and placebo-controlled trial of modafinil in children and adolescents with attention deficit and hyperactivity disorder. Psychiatry Res 2009, 168(3):234-237. 10.1016/j.psychres.2008.06.024, 19439364.
74. Arabgol F, Panaghi L, Hebrani P. Reboxetine versus methylphenidate in treatment of children and adolescents with attention deficit-hyperactivity disorder. Eur Child Adolesc Psychiatry 2009, 18(1):53-59. 10.1007/s00787-008-0705-9, 18563471.
75. Cohen-Yavin I, Yoran-Hegesh R, Strous RD, Kotler M, Weizman A, Spivak B. Efficacy of reboxetine in the treatment of attention-deficit/hyperactivity disorder in boys with intolerance to methylphenidate: an open-label, 8-week, methylphenidate-controlled trial. Clin Neuropharmacol 2009, 32(4):179-182. 10.1097/WNF.0b013e318183796d, 19644227.
76. Newcorn JH, Sutton VK, Weiss MD, Sumner CR. Clinical responses to atomoxetine in attention-deficit/hyperactivity disorder: the Integrated Data Exploratory Analysis (IDEA) study. J Am Acad Child Adolesc Psychiatry 2009, 48(5):511-518. 10.1097/CHI.0b013e31819c55b2, 19318988.
77. Garnock-Jones KP, Keating GM. Atomoxetine: a review of its use in attention-deficit hyperactivity disorder in children and adolescents. Paediatr Drugs 2009, 11(3):203-226. 10.2165/00148581-200911030-00005, 19445548.
78. Svanborg P, Thernlund G, Gustafsson PA, Hagglof B, Poole L, Kadesjo B. Efficacy and safety of atomoxetine as add-on to psychoeducation in the treatment of attention deficit/hyperactivity disorder: a randomized, double-blind, placebo-controlled study in stimulant-naive Swedish children and adolescents. Eur Child Adolesc Psychiatry 2009, 18(4):240-249. 10.1007/s00787-008-0725-5, 19156355.
79. Martenyi F, Zavadenko NN, Jarkova NB, Yarosh AA, Soldatenkova VO, Bardenstein LM, Kozlova IA, Neznanov NG, Maslova OI, Petrukhin AS, et al. Atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder: a 6-week, randomized, placebo-controlled, double-blind trial in Russia. Eur Child Adolesc Psychiatry 2010, 19(1):57-66. 10.1007/s00787-009-0042-7, 19568826.
80. Takahashi M, Takita Y, Yamazaki K, Hayashi T, Ichikawa H, Kambayashi Y, Koeda T, Oki J, Saito K, Takeshita K, et al. A randomized, double-blind, placebo-controlled study of atomoxetine in Japanese children and adolescents with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol 2009, 19(4):341-350. 10.1089/cap.2008.0154, 19702486.
81. Durell TM, Pumariega AJ, Rothe EM, Tamayo JM, Baron D, Williams D. Effects of open-label atomoxetine on African-American and Caucasian pediatric outpatients with attention-deficit/hyperactivity disorder. Ann Clin Psychiatry 2009, 21(1):26-37.
82. Dell'Agnello G, Maschietto D, Bravaccio C, Calamoneri F, Masi G, Curatolo P, Besana D, Mancini F, Rossi A, Poole L, et al. Atomoxetine hydrochloride in the treatment of children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder: A placebo-controlled Italian study. Eur Neuropsychopharmacol 2009, 19(11):822-834. 10.1016/j.euroneuro.2009.07.008, 19716683.
83. Hammerness P, Doyle R, Kotarski M, Georgiopoulos A, Joshi G, Zeitlin S, Biederman J. Atomoxetine in children with attention-deficit hyperactivity disorder with prior stimulant therapy: a prospective open-label study. Eur Child Adolesc Psychiatry 2009, 18(8):493-498. 10.1007/s00787-009-0017-8, 19377865.
84. Block SL, Kelsey D, Coury D, Lewis D, Quintana H, Sutton V, Schuh K, Allen AJ, Sumner C. Once-daily atomoxetine for treating pediatric attention-deficit/hyperactivity disorder: comparison of morning and evening dosing. Clin Pediatr (Phila) 2009, 48(7):723-733.
85. Wietecha LA, Williams DW, Herbert M, Melmed RD, Greenbaum M, Schuh K. Atomoxetine treatment in adolescents with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol 2009, 19(6):719-730. 10.1089/cap.2008.074, 20035590.
86. Paxton GA, Cranswick NE. Acute suicidality after commencing atomoxetine. J Paediatr Child Health 2008, 44(10):596-598. 10.1111/j.1440-1754.2008.01389.x, 19012633.
87. Whalen CK, Henker B, Ishikawa SS, Emmerson NA, Swindle R, Johnston JA. Atomoxetine versus stimulants in the community treatment of children with ADHD: an electronic diary study. J Atten Disord 2010, 13(4):391-400. 10.1177/1087054708325118, 19474461.
88. Buitelaar JK, Wilens TE, Zhang S, Ning Y, Feldman PD. Comparison of symptomatic versus functional changes in children and adolescents with ADHD during randomized, double-blind treatment with psychostimulants, atomoxetine, or placebo. J Child Psychol Psychiatry 2009, 50(3):335-342. 10.1111/j.1469-7610.2008.01960.x, 19309330.
89. Scahill L. Alpha-2 adrenergic agonists in children with inattention, hyperactivity and impulsiveness. CNS Drugs 2009, 23(Suppl 1):43-49.
90. Sallee FR, McGough J, Wigal T, Donahue J, Lyne A, Biederman J. Guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder: a placebo-controlled trial. J Am Acad Child Adolesc Psychiatry 2009, 48(2):155-165. 10.1097/CHI.0b013e318191769e, 19106767.
91. Biederman J, Melmed RD, Patel A, McBurnett K, Konow J, Lyne A, Scherer N. A randomized, double-blind, placebo-controlled study of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder. Pediatrics 2008, 121(1):e73-84. 10.1542/peds.2006-3695, 18166547.
92. Sallee FR, Lyne A, Wigal T, McGough JJ. Long-term safety and efficacy of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol 2009, 19(3):215-226. 10.1089/cap.2008.0080, 19519256.
93. Biederman J, Melmed RD, Patel A, McBurnett K, Donahue J, Lyne A. Long-term, open-label extension study of guanfacine extended release in children and adolescents with ADHD. CNS Spectr 2008, 13(12):1047-1055.
94. Faraone SV, Glatt SJ. Effects of extended-release guanfacine on ADHD symptoms and sedation-related adverse events in children with ADHD. J Atten Disord 2010, 13(5):532-538. 10.1177/1087054709332472, 19395648.
95. Cannon M, Pelham WH, Sallee FR, Palumbo DR, Bukstein O, Daviss WB. Effects of clonidine and methylphenidate on family quality of life in attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol 2009, 19(5):511-517. 10.1089/cap.2009.0008, 2830226, 19877975.
96. Spencer TJ, Greenbaum M, Ginsberg LD, Murphy WR. Safety and effectiveness of coadministration of guanfacine extended release and psychostimulants in children and adolescents with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol 2009, 19(5):501-510. 10.1089/cap.2008.0152, 2861960, 19877974.
97. Wilens TE, Hammerness P, Utzinger L, Schillinger M, Georgiopoulous A, Doyle RL, Martelon M, Brodziak K. An open study of adjunct OROS-methylphenidate in children and adolescents who are atomoxetine partial responders: I. Effectiveness. J Child Adolesc Psychopharmacol 2009, 19(5):485-492. 10.1089/cap.2008.0125, 2861954, 19877972.
98. Frolich J, Lehmkuhl G, Dopfner M. Algorithms for the medical treatment of Attention-Deficit/Hyperactivity Disorder with specific co-morbidities. Z Kinder Jugendpsychiatr Psychother 2010, 38(1):7-20. 10.1024/1422-4917.a000002, 20047172.
99. Chang K, Nayar D, Howe M, Rana M. Atomoxetine as an adjunct therapy in the treatment of co-morbid attention-deficit/hyperactivity disorder in children and adolescents with bipolar I or II disorder. J Child Adolesc Psychopharmacol 2009, 19(5):547-551. 10.1089/cap.2009.0030, 19877979.
100. Zeni CP, Tramontina S, Ketzer CR, Pheula GF, Rohde LA. Methylphenidate combined with aripiprazole in children and adolescents with bipolar disorder and attention-deficit/hyperactivity disorder: a randomized crossover trial. J Child Adolesc Psychopharmacol 2009, 19(5):553-561. 10.1089/cap.2009.0037, 19877980.
101. Golubchik P, Sever J, Weizman A. Influence of methylphenidate treatment on smoking behavior in adolescent girls with attention-deficit/hyperactivity and borderline personality disorders. Clin Neuropharmacol 2009, 32(5):239-242. 10.1097/WNF.0b013e3181a5d075, 19834989.
102. Weiss M, Panagiotopoulos C, Giles L, Gibbins C, Kuzeljevic B, Davidson J, Harrison R. A naturalistic study of predictors and risks of atypical antipsychotic use in an attention-deficit/hyperactivity disorder clinic. J Child Adolesc Psychopharmacol 2009, 19(5):575-582. 10.1089/cap.2009.0050, 19877982.
103. Blader JC, Schooler NR, Jensen PS, Pliszka SR, Kafantaris V. Adjunctive divalproex versus placebo for children with ADHD and aggression refractory to stimulant monotherapy. Am J Psychiatry 2009, 166(12):1392-1401. 10.1176/appi.ajp.2009.09020233, 2940237, 19884222.
104. Aman MG, Farmer CA, Hollway J, Arnold LE. Treatment of inattention, overactivity, and impulsiveness in autism spectrum disorders. Child Adolesc Psychiatr Clin N Am 2008, 17(4):713-738, vii. 10.1016/j.chc.2008.06.009, 18775366.
105. Lan Y, Zhang LL, Luo R. Attention deficit hyperactivity disorder in children: comparative efficacy of traditional Chinese medicine and methylphenidate. J Int Med Res 2009, 37(3):939-948.
106. Niederhofer H. Ginkgo biloba treating patients with attention-deficit disorder. Phytother Res 2010, 24(1):26-27. 10.1002/ptr.2854, 19441138.
107. Salehi B, Imani R, Mohammadi MR, Fallah J, Mohammadi M, Ghanizadeh A, Tasviechi AA, Vossoughi A, Rezazadeh SA, Akhondzadeh S. Ginkgo biloba for attention-deficit/hyperactivity disorder in children and adolescents: a double blind, randomized controlled trial. Prog Neuropsychopharmacol Biol Psychiatry 2010, 34(1):76-80. 10.1016/j.pnpbp.2009.09.026, 19815048.
108. Raz R, Carasso RL, Yehuda S. The influence of short-chain essential fatty acids on children with attention-deficit/hyperactivity disorder: a double-blind placebo-controlled study. J Child Adolesc Psychopharmacol 2009, 19(2):167-177. 10.1089/cap.2008.070, 19364294.
109. Johnson M, Ostlund S, Fransson G, Kadesjo B, Gillberg C. Omega-3/omega-6 fatty acids for attention deficit hyperactivity disorder: a randomized placebo-controlled trial in children and adolescents. J Atten Disord 2009, 12(5):394-401. 10.1177/1087054708316261, 18448859.
110. Arns M, de Ridder S, Strehl U, Breteler M, Coenen A. Efficacy of neurofeedback treatment in ADHD: the effects on inattention, impulsivity and hyperactivity: a meta-analysis. Clin EEG Neurosci 2009, 40(3):180-189.
111. Klingberg T, Fernell E, Olesen PJ, Johnson M, Gustafsson P, Dahlstrom K, Gillberg CG, Forssberg H, Westerberg H. Computerized training of working memory in children with ADHD--a randomized, controlled trial. J Am Acad Child Adolesc Psychiatry 2005, 44(2):177-186. 10.1097/00004583-200502000-00010, 15689731.
112. Kooij SJ, Bejerot S, Blackwell A, Caci H, Casas-Brugue M, Carpentier PJ, Edvinsson D, Fayyad J, Foeken K, Fitzgerald M, et al. European consensus statement on diagnosis and treatment of adult ADHD: The European Network Adult ADHD. BMC Psychiatry 2010, 10:67. 10.1186/1471-244X-10-67, 2942810, 20815868.
113. Faraone SV, Glatt SJ. A comparison of the efficacy of medications for adult attention-deficit/hyperactivity disorder using meta-analysis of effect sizes. J Clin Psychiatry 2009, 71(6):754-763.
114. Cascade E, Kalali AH, Weisler RH. Short-acting versus long-acting medications for the treatment of ADHD. Psychiatry (Edgmont) 2008, 5(8):24-27.
115. Wilens TE, Adler LA, Adams J, Sgambati S, Rotrosen J, Sawtelle R, Utzinger L, Fusillo S. Misuse and diversion of stimulants prescribed for ADHD: a systematic review of the literature. J Am Acad Child Adolesc Psychiatry 2008, 47(1):21-31. 10.1097/chi.0b013e31815a56f1, 18174822.
116. Antshel KM, Barkley R. Psychosocial interventions in attention deficit hyperactivity disorder. Child Adolesc Psychiatr Clin N Am 2008, 17(2):421-437, x. 10.1016/j.chc.2007.11.005, 18295154.
117. Ilardi SS, Craighead WE. The role of nonspecific factors in cognitive-behavior therapy for depression. Clinical Psychology: Science and Practice 1994, 1:138-156.
118. Blagys MD, Hilsenroth MJ. Distinctive activities of cognitive-behavioral therapy. A review of the comparative psychotherapy process literature. Clin Psychol Rev 2002, 22(5):671-706. 10.1016/S0272-7358(01)00117-9, 12113201.
119. Safren SA, Sprich S, Mimiaga MJ, Surman C, Knouse L, Groves M, Otto MW. Cognitive behavioral therapy vs relaxation with educational support for medication-treated adults with ADHD and persistent symptoms: a randomized controlled trial. Jama 2010, 304(8):875-880. 10.1001/jama.2010.1192, 20736471.
120. Bramham J, Young S, Bickerdike A, Spain D, McCartan D, Xenitidis K. Evaluation of group cognitive behavioral therapy for adults with ADHD. J Atten Disord 2009, 12(5):434-441. 10.1177/1087054708314596, 18310557.
121. Solanto MV, Marks DJ, Mitchell KJ, Wasserstein J, Kofman MD. Development of a new psychosocial treatment for adult ADHD. J Atten Disord 2008, 11(6):728-736.
122. Wilens TE, Biederman J, Faraone SV, Martelon M, Westerberg D, Spencer TJ. Presenting ADHD symptoms, subtypes, and comorbid disorders in clinically referred adults with ADHD. J Clin Psychiatry 2009, 70(11):1557-1562. 10.4088/JCP.08m04785pur, 2948439, 20031097.
123. Kadesjo B, Gillberg C. The comorbidity of ADHD in the general population of Swedish school-age children. J Child Psychol Psychiatry 2001, 42(4):487-492. 10.1111/1469-7610.00742, 11383964.
124. Rommelse NN, Altink ME, Fliers EA, Martin NC, Buschgens CJ, Hartman CA, Buitelaar JK, Faraone SV, Sergeant JA, Oosterlaan J. Comorbid problems in ADHD: degree of association, shared endophenotypes, and formation of distinct subtypes. Implications for a future DSM. J Abnorm Child Psychol 2009, 37(6):793-804. 10.1007/s10802-009-9312-6, 2708322, 19308723.
125. Lavigne JV, Lebailly SA, Hopkins J, Gouze KR, Binns HJ. The prevalence of ADHD, ODD, depression, and anxiety in a community sample of 4-year-olds. J Clin Child Adolesc Psychol 2009, 38(3):315-328. 10.1080/15374410902851382, 19437293.
126. Elia J, Borcherding BG, Rapoport JL, Keysor CS. Methylphenidate and dextroamphetamine treatments of hyperactivity: are there true nonresponders?. Psychiatry Res 1991, 36(2):141-155. 10.1016/0165-1781(91)90126-A, 2017529.
127. DuPaul GJ, Rapport MD. Does methylphenidate normalize the classroom performance of children with attention deficit disorder?. J Am Acad Child Adolesc Psychiatry 1993, 32(1):190-198. 10.1097/00004583-199301000-00027, 8428871.
128. Greenhill LL, Abikoff HB, Arnold LE, Cantwell DP, Conners CK, Elliott G, Hechtman L, Hinshaw SP, Hoza B, Jensen PS, et al. Medication treatment strategies in the MTA Study: relevance to clinicians and researchers. J Am Acad Child Adolesc Psychiatry 1996, 35(10):1304-1313. 10.1097/00004583-199610000-00017, 8885584.
129. Barkley RA, Murphy K, Fischer M. ADHD in Adults: What the Science Says. 2008, New York: Guilford Press.
130. Coghill DR, Rhodes SM, Matthews K. The neuropsychological effects of chronic methylphenidate on drug-naive boys with attention-deficit/hyperactivity disorder. Biol Psychiatry 2007, 62(9):954-962. 10.1016/j.biopsych.2006.12.030, 17543895.
131. Swanson J. Compliance with stimulants for attention-deficit/hyperactivity disorder: issues and approaches for improvement. CNS Drugs 2003, 17(2):117-131. 10.2165/00023210-200317020-00004, 12521359.
132. McGough JJ. Attention-deficit/hyperactivity disorder pharmacogenomics. Biol Psychiatry 2005, 57(11):1367-1373. 10.1016/j.biopsych.2004.10.021, 15950009.
133. Mick E, McGough JJ, Middleton FA, Neale B, Faraone SV. Genome-wide association study of blood pressure response to methylphenidate treatment of attention-deficit/hyperactivity disorder. Prog Neuropsychopharmacol Biol Psychiatry 2011,
134. Mick E, Neale B, Middleton FA, McGough JJ, Faraone SV. Genome-wide association study of response to methylphenidate in 187 children with attention-deficit/hyperactivity disorder. Am J Med Genet B Neuropsychiatr Genet 2008, 147B(8):1412-1418. 10.1002/ajmg.b.30865, 18821564.